others must develop high-performing health systems, and some of the ACA's Medicare and Medicaid reforms directly stimulate the development of accountable care organizations and patient-centered medical homes. Exchanges can help nurture these systems by organizing a receptive marketone in which each family can select the health care system it prefers, at a price reflecting the competitive value of that system, and can switch systems annually if dissatisfied.
One important constraint on the influence of consumer choice, however, is the relatively small number of people who will be covered through public exchanges. Two movements may increase the effect of consumer choice on the demand for integrated delivery systems. First, employers are beginning to use private exchanges, and if this trend accelerates, millions of employees may also be shopping among competing delivery systems. Second, several states have begun envisioning coordinated state purchasing strategies for Medicaid, government employees, and public exchanges that would drive payment and delivery-system reform.
If such purchasing initiatives are implemented as part of a series of coordinated initiatives to nourish innovative delivery systems, they could eventually garner enough market power to help reshape medical care. To succeed, purchasing coalitions would have to work closely with private insurance carriers and physicians to drive long-term change. This vision assumes that the politics of health care reform can accommodate the sustained effort necessary for systemic, evolutionary change executed through publicprivate collaborations. That is a tall order.
To achieve these ambitious objectives, exchanges must perform a balancing act familiar to any retailer. As essentially commercial enterprises, exchanges can lead "disruptive" change only so long as they are willing to follow customer preferences. This requirement is both an advantage and a disadvantage for a fundamentally conservative, market-oriented vehicle for health care reform. O n October 16, 2013, the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration (FDA) voted 9 to 2 against approval of Vascepa, a purified n-3 fatty acid formulation of ethyl eicosapentaenoic acid (EPA), for use as an adjunct to diet and in combination with a statin to reduce levels of triglycerides, nonhigh-density lipoprotein (non-HDL) cholesterol, apolipoprotein B, lowdensity lipoprotein (LDL) cholesterol, and very-low-density lipoprotein (VLDL) cholesterol in adult patients with mixed dyslipidemia and coronary heart disease or an equivalent risk of coronary heart disease. The sponsor and the FDA had previously agreed under a Special Protocol Assessment that triglyceride-lowering data from a 12-week study with lipid end points and 50% enrollment in a cardiovascular outcome trial would be sufficient for submission of a supplemental application seeking approval for the indication as an adjunct to a statin in patients with residually high triglyceride levels. After that agreement was reached, however, several clinical trials were published showing no cardiovascular benefit from drugs that lowered triglyceride levels or increased HDL cholesterol levels (see table) .
This new information called into question the clinical benefit of the triglyceride target and the rationale for using triglyceride levels as a surrogate end point for regulatory approval. These issues affect clinical decisions, since several drugs are available for lowering triglyceride levels (e.g., fibrates, niacin, and n-3 fatty acids). Other drugs in development also target previously untried mechanisms for modulating cholesterol levels, under the assumption that improving specific aspects of the lipid profile will translate into a reduced risk of major cardiovascular events.
The FDA approved Vascepa in 2012 for use in patients with severe hypertriglyceridemia (triglyceride level, ≥500 mg per deciliter [5.6 mmol per liter]), on the presumption that lowering very high triglyceride concentrations would reduce the risk of acute pancreatitis, despite a lack of outcome data on that end point. The October 2013 advisory committee meeting focused primarily on the results of the Effect of AMR101 (Ethyl Icosapentate) on Triglyceride Levels in Patients on Statins with High Triglyceride Levels (ANCHOR) trial, which involved 702 participants who were taking a statin drug aiming for an LDL cholesterol target of less than 115 mg per deciliter (2.97 mmol per liter) but still had triglyceride levels of 185 to 499 mg per deciliter (2.09 to 5.63 mmol per liter) and non-HDL cholesterol levels of at least 100 mg per deciliter (2.6 mmol per liter). These patients were thought to be at substantial cardiovascular risk despite control of LDL cholesterol levels. The results at 12 weeks showed a placebo-corrected 21% reduction in triglyceride levels with a Vascepa dose of 4 g per day and a 10% reduction with 2 g per day -both significant. There were significant reductions in lev- ) . At that meeting, the FDA presented meta-analyses of studies of n-3 fatty acids that revealed mixed results for cardiovascular outcomes. The most favorable trial was the Japan EPA Lipid Intervention Study (JELIS), which showed a positive effect of 1800 mg per day of EPA on a broad cardiovascular end point, driven primarily by reductions in nonfatal myocardial infarctions, unstable angina, and cardiac revascularization. This trial had major design limitations, however, including the facts that it was open-label and used lowdose background statin therapy. There are similar concerns regarding HDL cholesterol, since trials of torcetrapib and dalcetrapib did not show clinical benefits.
The deliberations over Vascepa highlight several challenging issues in the development of new treatments for lipid disorders. There is now uncertainty regarding the regulatory approach of approving drugs on the basis of favorable lipid effects and evaluating clinical benefit after approval. If a new drug has a plausible mechanism of action, the intended patient population is well defined, the benefit of a particular lipid surrogate end point is clear, and there is no safety concern, then is it reasonable to bring the drug to market while the definitive cardiovascular outcome trial is ongoing? In judging the risk-benefit ratio in the absence of clinical outcomes data, the drug's safety would need to be well defined. This approach would have the potentially positive effect of allowing patients to use the drug while the outcome trial was being completed -an advantage if the drug were subsequently shown to improve cardiovascular outcomes. Copyright © 2014 Massachusetts Medical Society. All rights reserved.
